Neoplasia最新文献

{"title":"Tumor microenvironment(TME) and single-source dual-energy CT(ssDECT) on assessment of inconformity between RECIST1.1 and pathological remission in neoadjuvant immunotherapy of NSCLC","authors":"Chao Sun ,&nbsp;Xiaobo Ma ,&nbsp;Fanyang Meng ,&nbsp;Xi Chen ,&nbsp;Xu Wang ,&nbsp;Wenyu Sun ,&nbsp;Yinghui Xu ,&nbsp;Hua He ,&nbsp;Huimao Zhang ,&nbsp;Kewei Ma","doi":"10.1016/j.neo.2024.100977","DOIUrl":"https://doi.org/10.1016/j.neo.2024.100977","url":null,"abstract":"<div><h3>Background</h3><p>The inconformity (IC) between pathological and imaging remissions after neoadjuvant immunotherapy in patients with NSCLC can affect the evaluation of curative effect of neoadjuvant therapy and the decision regarding the chance of surgery.</p></div><div><h3>Materials and methods</h3><p>Patients who achieved disease control(CR/PR/SD) after neoadjuvant chemoimmunotherapy from a clinical trial (NCT04326153) and after neoadjuvant chemotherapy during the same period were enrolled in this study. All patients underwent radical resection and systematic mediastinal lymphadenectomy after neoadjuvant treatments. The pathological remission, immunohistochemistry (CD4, CD8, CD20, CD56, FoxP3, CD68, CD163, CD11b tumor-infiltrating lymphocytes, or macrophages), and single-source dual-energy computed tomography (ssDECT) scans were assessed. The IC between imaging remission by CT and pathological remission was investigated. The underlying cause of IC, the correlation between IC and DFS, and prognostic biomarkers were explored.</p></div><div><h3>Results</h3><p>After neoadjuvant immunotherapy, enhanced immune killing and reduced immunosuppressive performance were observed. 70 % of neoadjuvant chemoimmunotherapy patients were in high/medium IC level. Massive necrosis and repair around and inside the cancer nest were the main pathological changes observed 30–45 days post-treatment with PD1/PD-L1 antibody and were the main causes of IC between the pathology and imaging responses after neoadjuvant immunotherapy. High IC and preoperative CD8 expression (H score ≥ 3) indicate a high pathological response rate and prolonged DFS. Iodine material density ssDECT images showed that the iodine content in the lesion causes hyperattenuation in post-neoadjuvant lesion in PCR patient.</p></div><div><h3>Conclusions</h3><p>Compared to chemotherapy and targeted therapy, the efficacy of neoadjuvant immunotherapy was underestimated based on the RECIST criteria due to the unique antitumor therapeutic mechanism. Preoperative CD8+ expression and ssDECT predict this IC and evaluate the residual tumor cells. This is of great significance for screening immune beneficiaries and making more accurate judgments about the timing of surgery.</p></div>","PeriodicalId":18917,"journal":{"name":"Neoplasia","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1476558624000149/pdfft?md5=5b73b126ae6603596dae7e21b11ea037&pid=1-s2.0-S1476558624000149-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139727030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A liquid biomarker signature of inflammatory proteins accurately predicts early pancreatic cancer progression during FOLFIRINOX chemotherapy","authors":"Casper W.F. van Eijck ,&nbsp;Sergio Sabroso-Lasa ,&nbsp;Gaby J. Strijk ,&nbsp;Dana A.M. Mustafa ,&nbsp;Amine Fellah ,&nbsp;Bas Groot Koerkamp ,&nbsp;Núria Malats ,&nbsp;Casper H.J. van Eijck","doi":"10.1016/j.neo.2024.100975","DOIUrl":"10.1016/j.neo.2024.100975","url":null,"abstract":"<div><h3>Background</h3><p>Pancreatic ductal adenocarcinoma (PDAC) is often treated with FOLFIRINOX, a chemotherapy associated with high toxicity rates and variable efficacy. Therefore, it is crucial to identify patients at risk of early progression during treatment. This study aims to explore the potential of a multi-omics biomarker for predicting early PDAC progression by employing an in-depth mathematical modeling approach.</p></div><div><h3>Methods</h3><p>Blood samples were collected from 58 PDAC patients undergoing FOLFIRINOX before and after the first cycle. These samples underwent gene (GEP) and inflammatory protein expression profiling (IPEP). We explored the predictive potential of exclusively IPEP through Stepwise (Backward) Multivariate Logistic Regression modeling. Additionally, we integrated GEP and IPEP using Bayesian Kernel Regression modeling, aiming to enhance predictive performance. Ultimately, the FOLFIRINOX IPEP (FFX-IPEP) signature was developed.</p></div><div><h3>Results</h3><p>Our findings revealed that proteins exhibited superior predictive accuracy than genes. Consequently, the FFX-IPEP signature consisted of six proteins: AMN, BANK1, IL1RL2, ITGB6, MYO9B, and PRSS8. The signature effectively identified patients transitioning from disease control to progression early during FOLFIRINOX, achieving remarkable predictive accuracy with an AUC of 0.89 in an independent test set. Importantly, the FFX-IPEP signature outperformed the conventional CA19-9 tumor marker.</p></div><div><h3>Conclusions</h3><p>Our six-protein FFX-IPEP signature holds solid potential as a liquid biomarker for the early prediction of PDAC progression during toxic FOLFIRINOX chemotherapy. Further validation in an external cohort is crucial to confirm the utility of the FFX-IPEP signature. Future studies should expand to predict progression under different chemotherapies to enhance the guidance of personalized treatment selection in PDAC.</p></div>","PeriodicalId":18917,"journal":{"name":"Neoplasia","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1476558624000125/pdfft?md5=0c207c5a52ef469c43f36332d18b03c0&pid=1-s2.0-S1476558624000125-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139713242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular heterogeneity in histomorphologic subtypes of lung adeno carcinoma represents a challenge for treatment decision","authors":"Tobias Kolb,&nbsp;Sarah Müller,&nbsp;Peter Möller,&nbsp;Thomas F.E. Barth,&nbsp;Ralf Marienfeld","doi":"10.1016/j.neo.2023.100955","DOIUrl":"https://doi.org/10.1016/j.neo.2023.100955","url":null,"abstract":"<div><p>Lung cancer is the leading cause in cancer related death, with non-small cell lung cancer (NSCLC) being the most frequent subtype. The importance of NSCLC is reflected by the various targeted therapy options especially for NSCLC adenocarcinomas (lung adeno carcinoma (LUAD)) as well as a set of options for immune therapies. However, despite these therapy advances, the majority of patients do not show a long-term response to either targeted therapy or immune checkpoint inhibition. One reason for treatment failure appears to be the NSCLC tumor heterogeneity. NSCLC heterogeneity might lead to an insufficient molecular characterization of a given sample due to the limited tumor material used for pathological assessment as the majority of analyses is performed on small biopsies. To get a more detailed insight into the tumor heterogeneity of NSCLC LUAD, especially in the light of its different histomorphological growth patterns, we analysed isolated NSCLC growth pattern areas and the corresponding entire tumor samples of a cohort of 31 NSLCS LUAD patients and compared their mutational landscape and their expression profiles. While significant differences of complex biomarkers, like tumor mutational burden (TMB) or microsatellite instability (MSI), were not detected between the five growth patterns -lepidic, papillary, micropapillary, acinar, and solid- we observed various subclonal mutations and copy number variants. Moreover, RNASeq analysis revealed growth pattern specific expression profiles affecting cellular processes like apoptosis, metastasis and proliferation. Taken together, our data provide novel insights into the tumor heterogeneity of LUAD required to overcome tumor heterogeneity related therapy resistance.</p></div>","PeriodicalId":18917,"journal":{"name":"Neoplasia","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1476558623000787/pdfft?md5=a6e654e3ba3f9ad4fea8e2d4b78acb20&pid=1-s2.0-S1476558623000787-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139674449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reciprocal regulation of lncRNA MEF and c-Myc drives colorectal cancer tumorigenesis","authors":"Shuang Wu ,&nbsp;Xiangyu Dai ,&nbsp;Zhipu Zhu ,&nbsp;Dianhui Fan ,&nbsp;Su Jiang ,&nbsp;Yi Dong ,&nbsp;Bing Chen ,&nbsp;Qi Xie ,&nbsp;Zhihui Yao ,&nbsp;Qun Li ,&nbsp;Rick Francis Thorne ,&nbsp;Yao Lu ,&nbsp;Hao Gu ,&nbsp;Wanglai Hu","doi":"10.1016/j.neo.2024.100971","DOIUrl":"https://doi.org/10.1016/j.neo.2024.100971","url":null,"abstract":"<div><p>More than half of all cancers demonstrate aberrant c-Myc expression, making this arguably the most important human oncogene. Deregulated long non-coding RNAs (lncRNAs) are also commonly implicated in tumorigenesis, and some limited examples have been established where lncRNAs act as biological tuners of c-Myc expression and activity. Here, we demonstrate that the lncRNA denoted c-Myc Enhancing Factor (MEF) enjoys a cooperative relationship with c-Myc, both as a transcriptional target and driver of c-Myc expression. Mechanistically, MEF functions by binding to and stabilizing the expression of hnRNPK in colorectal cancer cells. The MEF-hnRNPK interaction serves to disrupt binding between hnRNPK and the E3 ubiquitin ligase TRIM25, which attenuates TRIM25-dependent hnRNPK ubiquitination and proteasomal destruction. In turn, the stabilization of hnRNPK through MEF enhances c-Myc expression by augmenting the translation c-Myc. Moreover, modulating the expression of MEF in shRNA-mediated knockdown and overexpression studies revealed that MEF expression is essential for colorectal cancer cell proliferation and survival, both in vitro and in vivo. From the clinical perspective, we show that MEF expression is differentially increased in colorectal cancer tissues compared to normal adjacent tissues. Further, correlations exist between MEF, c-Myc, and hnRNPK suggesting the MEF-c-Myc positive feedback loop is active in patients. Together these data demonstrate that MEF is a pivotal partner of the c-Myc network and propose MEF as a valuable therapeutic target for colorectal cancer.</p></div>","PeriodicalId":18917,"journal":{"name":"Neoplasia","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1476558624000083/pdfft?md5=1889e62be21c43ba26a09b22058a81f1&pid=1-s2.0-S1476558624000083-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139652882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-throughput sequencing and in-silico analysis confirm pathogenicity of novel MSH3 variants in African American colorectal cancer","authors":"Mudasir Rashid ,&nbsp;Rumaisa Rashid ,&nbsp;Nikhil Gadewal ,&nbsp;John M. Carethers ,&nbsp;Minoru Koi ,&nbsp;Hassan Brim ,&nbsp;Hassan Ashktorab","doi":"10.1016/j.neo.2024.100970","DOIUrl":"10.1016/j.neo.2024.100970","url":null,"abstract":"<div><p>The maintenance of DNA sequence integrity is critical to avoid accumulation of cancer-causing mutations. Inactivation of DNA Mismatch Repair (MMR) genes (e.g., <em>MLH1</em> and <em>MSH2</em>) is common among many cancers, including colorectal cancer (CRC) and is the driver of classic microsatellite instability (MSI) in tumors. Somatic <em>MSH3</em> alterations have been linked to a specific form of MSI called elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) that is associated with patient poor prognosis and elevated among African American (AA) rectal cancer patients. Genetic variants of <em>MSH3</em> and their pathogenicity vary among different populations, such as among AA, which are not well-represented in publicly available databases. Targeted exome sequencing of <em>MSH3</em> among AA CRC samples followed by computational bioinformatic pipeline and molecular dynamic simulation analysis approach confirmed six identified <em>MSH3</em> variants (c.G1237A, c.C2759T, c.G1397A, c.G2926A, c.C3028T, c.G3241A) that corresponded to MSH3 amino-acid changes (<em>p.</em>E413K; <em>p.</em>S466N; <em>p.</em>S920F; <em>p.</em>E976K; <em>p.</em>H1010Y; <em>p.</em>E1081K). All identified <em>MSH3</em> variants were non-synonymous, novel, pathogenic, and show loss or gain of hydrogen bonding, ionic bonding, hydrophobic bonding, and disulfide bonding and have a deleterious effect on the structure of MSH3 protein. Some variants were located within the ATPase site of MSH3, affecting ATP hydrolysis that is critical for MSH3′s function. Other variants were in the MSH3-MSH2 interacting domain, important for MSH3’s binding to MSH2. Overall, our data suggest that these variants among AA CRC patients affect the function of MSH3 making them pathogenic and likely contributing to the development or advancement of CRC among AA. Further clarifying functional studies will be necessary to fully understand the impact of these variants on MSH3 function and CRC development in AA patients.</p></div>","PeriodicalId":18917,"journal":{"name":"Neoplasia","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1476558624000071/pdfft?md5=cab8958f4c72a1490aa1f60da31e9c51&pid=1-s2.0-S1476558624000071-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139570365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FBXO38 deficiency promotes lysosome-dependent STING degradation and inhibits cGAS–STING pathway activation","authors":"Yijia Wu ,&nbsp;Yao Lin ,&nbsp;Feiyang Shen ,&nbsp;Rui Huang ,&nbsp;Zhe Zhang ,&nbsp;Min Zhou ,&nbsp;Yan Fang ,&nbsp;Jianfeng Shen ,&nbsp;Xianqun Fan","doi":"10.1016/j.neo.2024.100973","DOIUrl":"10.1016/j.neo.2024.100973","url":null,"abstract":"<div><p>F-box only protein 38 (FBXO38) is a member of the F-box family that mediates the ubiquitination and proteasome degradation of programmed death 1 (PD-1), and thus has important effects on T cell-related immunity. While its powerful role in adaptive immunity has attracted much attention, its regulatory roles in innate immune pathways remain unknown. The cyclic GMP–AMP synthase–stimulator of interferon genes (cGAS–STING) pathway is an important innate immune pathway that regulates type I interferons. STING protein is the core component of this pathway. In this study, we identified that FBXO38 deficiency enhanced tumor proliferation and reduced tumor CD8⁺ T cells infiltration. Loss of FBXO38 resulted in reduced STING protein levels <em>in vitro</em> and <em>in vivo</em>, further leading to preventing cGAS–STING pathway activation, and decreased downstream product IFNA1 and CCL5. The mechanism of reduced STING protein was associated with lysosome-mediated degradation rather than proteasomal function. Our results demonstrate a critical role for FBXO38 in the cGAS–STING pathway.</p></div>","PeriodicalId":18917,"journal":{"name":"Neoplasia","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1476558624000101/pdfft?md5=3e3dfa7185c2f241393c6b7aee4f9571&pid=1-s2.0-S1476558624000101-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139560887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DNA methylation landscape reveals GNAS as a decitabine-responsive marker in patients with acute myeloid leukemia","authors":"Shujiao He ,&nbsp;Yan Li ,&nbsp;Lei Wang ,&nbsp;Yisheng Li ,&nbsp;Lu Xu ,&nbsp;Diya Cai ,&nbsp;Jingfeng Zhou ,&nbsp;Li Yu","doi":"10.1016/j.neo.2024.100965","DOIUrl":"https://doi.org/10.1016/j.neo.2024.100965","url":null,"abstract":"<div><h3>Background</h3><p>The demethylation agent decitabine (DAC) is a pivotal non-intensive alternative treatment for acute myeloid leukemia (AML). However, patient responses to DAC are highly variable, and predictive biomarkers are warranted. Herein, the DNA methylation landscape of patients treated with a DAC-based combination regimen was compared with that of patients treated with standard chemotherapy to develop a molecular approach for predicting clinical response to DAC.</p></div><div><h3>Methods</h3><p>Twenty-five non-M3 AML patients were enrolled and subjected to DNA methylation sequencing and profiling to identify differentially methylated regions (DMRs) and genes of interest. Moreover, the effects of a DAC-based regimen on apoptosis and gene expression were explored using Kasumi-1 and K562 cells.</p></div><div><h3>Results</h3><p>Overall, we identified 541 DMRs that were specifically responsive to DAC, among which 172 DMRs showed hypomethylation patterns upon treatment and were aligned with the promoter regions of 182 genes. In particular, <em>GNAS</em> was identified as a critical DAC-responsive gene, with <em>in vitro GNAS</em> downregulation leading to reduced cell apoptosis induced by DAC and cytarabine combo treatment.</p></div><div><h3>Conclusions</h3><p>We found that <em>GNAS</em> is a DAC-sensitive gene in AML and may serve as a prognostic biomarker to assess the responsiveness of patients with AML to DAC-based therapy.</p></div>","PeriodicalId":18917,"journal":{"name":"Neoplasia","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1476558624000022/pdfft?md5=8d1cc70ba27992ae5231268730b0533b&pid=1-s2.0-S1476558624000022-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139505556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tozasertib activates anti-tumor immunity through decreasing regulatory T cells in melanoma","authors":"Qiaoling Wang ,&nbsp;Wuyi Liu ,&nbsp;Huyue Zhou ,&nbsp;Wenjing Lai ,&nbsp;Changpeng Hu ,&nbsp;Yue Dai ,&nbsp;Guobing Li ,&nbsp;Rong Zhang ,&nbsp;Yu Zhao","doi":"10.1016/j.neo.2024.100966","DOIUrl":"https://doi.org/10.1016/j.neo.2024.100966","url":null,"abstract":"<div><p>Although immune checkpoint therapy has significantly improved the prognosis of patients with melanoma, urgent attention still needs to be paid to the low patient response rates and the challenges of precisely identifying patients before treatment. Therefore, it is crucial to investigate novel immunosuppressive mechanisms and targets in the tumor microenvironment in order to reverse tumor immune escape. In this study, we found that the cell cycle checkpoint Aurora kinase B (AURKB) suppressed the anti-tumor immune response, and its inhibitor, Tozasertib, effectively activated T lymphocyte cytokine release <em>in vitro</em> and anti-tumor immunity <em>in vivo</em>. Tozasertib significantly inhibited melanoma xenograft tumor growth by decreasing the number of inhibitory CD4⁺ T_reg cells in the tumors, which, in turn, activated CD8⁺ T cells. Single-cell analysis revealed that AURKB suppressed anti-tumor immunity by increasing MIF-CD74/CXCR4 signaling between tumor cells and lymphocytes. Our study suggests that AURKB is a newly identified anti-tumor immunity suppressor, whose inhibitors may be developed as novel anti-tumor immunity drugs and may have synergistic anti-melanoma effects with immune checkpoint therapies.</p></div>","PeriodicalId":18917,"journal":{"name":"Neoplasia","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1476558624000034/pdfft?md5=33673410ed43965e3456d9e32baef878&pid=1-s2.0-S1476558624000034-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139488062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AEBP1 promotes papillary thyroid cancer progression by activating BMP4 signaling","authors":"Gaoda Ju ,&nbsp;Tao Xing ,&nbsp;Miaomiao Xu ,&nbsp;Xin Zhang ,&nbsp;Yuqing Sun ,&nbsp;Zhuanzhuan Mu ,&nbsp;Di Sun ,&nbsp;Sen Miao ,&nbsp;Li Li ,&nbsp;Jun Liang ,&nbsp;Yansong Lin","doi":"10.1016/j.neo.2024.100972","DOIUrl":"https://doi.org/10.1016/j.neo.2024.100972","url":null,"abstract":"<div><p>Papillary thyroid cancer (PTC) is the most prevalent endocrine cancer worldwide. Approximately 30 % of PTC patients will progress into the advanced or metastatic stage and have a relatively poor prognosis. It is well known that epithelial-mesenchymal transition (EMT) plays a pivotal role in thyroid cancer metastasis, resistance to therapy, and recurrence. Clarifying the molecular mechanisms of EMT in PTC progression will help develop the targeted therapy of PTC. The aberrant expression of some transcription factors (TFs) participated in many pathological processes of cancers including EMT. In this study, by performing bioinformatics analysis, adipocyte enhancer-binding protein 1 (AEBP1) was screened as a pivotal TF that promoted EMT and tumor progression in PTC. <em>In vitro</em> experiments indicated that knockout of AEBP1 can inhibit the growth and invasion of PTC cells and reduce the expression of EMT markers including N-cadherin, TWIST1, and ZEB2. In the xenograft model, knockout of AEBP1 inhibited the growth and lung metastasis of PTC cells. By performing RNA-sequencing, dual-luciferase reporter assay, and chromatin immunoprecipitation assay, Bone morphogenetic protein 4 (BMP4) was identified as a downstream target of AEBP1. Over-expression of BMP4 can rescue the inhibitory effects of AEBP1 knockout on the growth, invasion, and EMT phenotype of PTC cells. In conclusion, these findings demonstrated that AEBP1 plays a critical role in PTC progression by regulating BMP4 expression and the AEBP1-BMP4 axis may present novel therapeutic targets for PTC treatment.</p></div>","PeriodicalId":18917,"journal":{"name":"Neoplasia","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1476558624000095/pdfft?md5=c837e23464255546dc30a4b083af36d3&pid=1-s2.0-S1476558624000095-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139487941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine Learning-assisted immunophenotyping of peripheral blood identifies innate immune cells as best predictor of response to induction chemo-immunotherapy in head and neck squamous cell carcinoma – knowledge obtained from the CheckRad-CD8 trial","authors":"Markus Hecht ,&nbsp;Benjamin Frey ,&nbsp;Udo S. Gaipl ,&nbsp;Xie Tianyu ,&nbsp;Markus Eckstein ,&nbsp;Anna-Jasmina Donaubauer ,&nbsp;Gunther Klautke ,&nbsp;Thomas Illmer ,&nbsp;Maximilian Fleischmann ,&nbsp;Simon Laban ,&nbsp;Matthias G. Hautmann ,&nbsp;Bálint Tamaskovics ,&nbsp;Thomas B. Brunner ,&nbsp;Ina Becker ,&nbsp;Jian-Guo Zhou ,&nbsp;Arndt Hartmann ,&nbsp;Rainer Fietkau ,&nbsp;Heinrich Iro ,&nbsp;Michael Döllinger ,&nbsp;Antoniu-Oreste Gostian ,&nbsp;Andreas M. Kist","doi":"10.1016/j.neo.2023.100953","DOIUrl":"https://doi.org/10.1016/j.neo.2023.100953","url":null,"abstract":"<div><h3>Purpose</h3><p>Individual prediction of treatment response is crucial for personalized treatment in multimodal approaches against head-and-neck squamous cell carcinoma (HNSCC). So far, no reliable predictive parameters for treatment schemes containing immunotherapy have been identified. This study aims to predict treatment response to induction chemo-immunotherapy based on the peripheral blood immune status in patients with locally advanced HNSCC.</p></div><div><h3>Methods</h3><p>The peripheral blood immune phenotype was assessed in whole blood samples in patients treated in the phase II CheckRad-CD8 trial as part of the pre-planned translational research program. Blood samples were analyzed by multicolor flow cytometry before (T1) and after (T2) induction chemo-immunotherapy with cisplatin/docetaxel/durvalumab/tremelimumab. Machine Learning techniques were used to predict pathological complete response (pCR) after induction therapy.</p></div><div><h3>Results</h3><p>The tested classifier methods (LDA, SVM, LR, RF, DT, and XGBoost) allowed a distinct prediction of pCR. Highest accuracy was achieved with a low number of features represented as principal components. Immune parameters obtained from the absolute difference (lT2-T1l) allowed the best prediction of pCR. In general, less than 30 parameters and at most 10 principal components were needed for highly accurate predictions. Across several datasets, cells of the innate immune system such as polymorphonuclear cells, monocytes, and plasmacytoid dendritic cells are most prominent.</p></div><div><h3>Conclusions</h3><p>Our analyses imply that alterations of the innate immune cell distribution in the peripheral blood following induction chemo-immuno-therapy is highly predictive for pCR in HNSCC.</p></div>","PeriodicalId":18917,"journal":{"name":"Neoplasia","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1476558623000775/pdfft?md5=5352eae647a6ea03f6935c02db67c2cc&pid=1-s2.0-S1476558623000775-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139480210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}